Validating CaMKK2 as a Rational Treatment Target for Bipolar Disorder

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2001817

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Bipolar disorder is a disabling, chronic mental illness that profoundly impairs the ability of affected individuals to function in daily life. Existing treatments for bipolar disorder are inadequate and lack the necessary efficacy and tolerability required for long-term therapy. This project will validate the enzyme, CaMKK2, as a rational treatment target for bipolar disorder, which will guide the development of more effective and safer drugs to improve patient outcomes.

Funded Activity Details

Start Date: 01-01-2020

End Date: 01-01-2023

Funding Scheme: Ideas Grants

Funding Amount: $688,175.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug discovery | protein kinases | psychopharmacology | signalling pathways

Related Links